Biosolution Co., Ltd. Overview
Biosolution is a Seoul-based advanced regenerative medicine company. It is one of the few Korean cell-therapy developers with several marketed, reimbursed products and recurring revenue. Its franchise is cartilage regeneration. CartiLife is an autologous, scaffold-free, costal-cartilage-derived chondrocyte bead therapy for knee cartilage defects. It moved from conditional (2019) to full Korean approval (April 2025), holds FDA RMAT designation, has completed a US Phase 2, and in April 2026 became the first Korean cell therapy approved for sale in China's Hainan Boao Lecheng medical pilot zone. Two follow-on assets extend the platform: the allogeneic pellet Cartiroid (Australian Phase 1/2) and the injectable spheroid Spherocure (Korean Phase 1/2a). Burn-care therapies (KeraHeal, KeraHeal-Allo), OECD-listed human tissue models, and stem-cell cosmetic ingredients add diversified but sub-scale revenue. The company remains loss-making at the operating level (FY2025 operating loss KRW 4.3bn on revenue of KRW 15.2bn). It also controls the restructured gene-therapy developer Helixmith.
What the company does
Biosolution develops, manufactures and sells cell-based products built on two core competencies: somatic and stem-cell culture, and tissue engineering. Commercial activity falls into four streams [company website; Bloter/Daum, Apr 2026; Butler, Q1 2026]:
-
Cell therapeutics. Autologous and allogeneic products for cartilage defects and burns:
-
CartiLife (knee cartilage)
-
KeraHeal (autologous spray-type keratinocytes for severe burns)
-
KeraHeal-Allo (allogeneic keratinocytes in thermosensitive hydrogel for deep second-degree burns) This is the largest stream: 65.3% of FY2025 revenue and about 71% of Q1 2026 revenue.
-
-
Cosmetic materials and finished cosmetics. Human stem-cell conditioned media (STEMSOO / STem水), peptide and exosome ingredients, natural ingredients, and a direct-to-consumer brand mall (stemsoo.com). 18.7% of FY2025 revenue.
-
Human tissue models and non-clinical testing services. KeraSkin skin model, MCTT HCE epithelial model, plus cartilage and intestinal models. Sold as kits and as GLP-certified alternative-to-animal testing (CRO) services. 10.1% of FY2025 revenue.
-
Medical devices / merchandise and other services. For example, the StemMobile-Gel wound dressing. About 6% of FY2025 revenue combined.
Business and revenue model
| Revenue type (FY2025) | KRW Bn | Share of revenue (%) |
|---|---|---|
| Products: cell therapies | 9.9 | 65.3 |
| Products: cosmetic materials and finished goods | 2.8 | 18.7 |
| Products and services: human tissue models | 1.5 | 10.1 |
| Merchandise (incl. medical devices) | 0.4 | about 2.6 (derived) |
| Other services | 0.5 | about 3.3 (derived) |
Product sales (dominant): Cell therapies are manufactured per patient or per batch in the company's Seoul GMP facility and sold to hospitals. CartiLife has been sold through a direct sales team since 2023 [KIRS, Jul 2024; Research Arum, Mar 2023]. KeraHeal-Allo was historically distributed exclusively in Korea by Mundipharma Korea under a May 2016 agreement [Medigate News, May 2016]. Whether that agreement is still in force is not publicly disclosed.
Licensing / technology fees (emerging): In China (Hainan), a local partner handles sales. Biosolution receives a share of the treatment price as a technology fee [ValueFinder via Asia Economy, Jun 2026]. Management describes procedure-volume growth there as flowing to revenue without large local capital investment [Money Today, Aug 2026]. Out-licensing of CartiLife (US Phase 3 and other ex-Korea rights), Cartiroid and Spherocure is an explicit goal [Asia Economy, Jun 2026].
Services: GLP non-clinical testing using in-house tissue models, plus cosmetic ingredient development and consulting [company website].
Subscription: none disclosed.
Product vs. service mix, FY2025: [Bloter/Daum, Apr 2026, citing company IR]:
Value chain position
Biosolution is vertically integrated from cell-sourcing protocol and process development through GMP manufacture and quality release, and into hospital sales in Korea. For CartiLife the chain runs:
-
Biopsy of the patient's costal (rib) cartilage.
-
Cell isolation and culture in Biosolution's Seoul GMP plant.
-
Formation of scaffold-free cartilage beads.
-
Implantation by an orthopaedic surgeon.
In China the company has chosen an asset-light model: production at the partner Boao International Hospital's own GMP facility, local sales by the partner, and a technology fee to Biosolution [Dailypharm, Aug 2026]. In tissue models it is both a kit manufacturer and a testing-service provider.
Customers and end markets
| End market | Customer type | Products |
|---|---|---|
| Orthopaedics: cartilage defects / early knee OA | Tertiary and general hospitals, specialty joint hospitals (Korea); Boao International Hospital (China) | CartiLife; pipeline Cartiroid, Spherocure |
| Burns and wound care | Burn-specialist hospitals; reimbursed under national health insurance and industrial-accident insurance | KeraHeal, KeraHeal-Allo; StemMobile-Gel |
| Chemical, cosmetic, drug and device safety testing | Cosmetics, pharma, chemical and device makers; regulators | KeraSkin, MCTT HCE and other models; GLP testing |
| Cosmetics | Cosmetic brand owners (B2B ingredients), consumers (B2C) | STEMSOO, BSP-11, exosome ingredients |
Company self-description vs. independent characterisation
| Tier | Product | Status |
|---|---|---|
| Premium autologous | CartiLife | Marketed in Korea and Hainan |
| Mass-producible allogeneic | Cartiroid | Clinical |
| Non-surgical injectable DMOAD candidate | Spherocure | Clinical |
Company's own description. The website presents Biosolution as "A Leading Company of Cell-Based Biotechnology". Filings-based database summaries describe it as a cell-based biotechnology company that manufactures and sells cell-therapy products, develops cell-therapeutics technology, and produces human tissue models for toxicity and efficacy screening [Morningstar profile].
Independent characterisation. Biosolution is best viewed as a small, commercial-stage regenerative-medicine company whose valuation depends on one platform: costal chondrocyte tissue engineering. That platform has three tiers:
Around this core sit modest, steady businesses (burns, tissue models, cosmetics). These provide about KRW 5–6bn of non-cartilage revenue but do not cover R&D. The Helixmith stake adds a large, volatile equity-accounted asset and an option on Helixmith's assets: Engensis royalties from China, GMP and animal facilities, and cash. It is not an operating business that Biosolution consolidates.
Strategy
Stated strategic themes (management, 2026)
-
"Revenue above all." In his 2026 New Year message, CEO Lee made revenue expansion the year's overriding priority. He said that after years of technical validation the goal now is sales, with domestic CartiLife expansion first [TheBell/Money Today, Jan 2026].
-
A pipeline "triangle" on one platform [TheBell, Jan 2026; Money Today, Aug 2026]:
-
CartiLife: autologous, premium, surgical.
-
Cartiroid: allogeneic, mass-producible.
-
Spherocure: injectable, non-surgical, DMOAD candidate. Management frames this as covering every stage of cartilage-defect and knee-OA treatment, with CartiLife supporting the floor of the valuation and Spherocure extending the upside.
-
-
China first, via regulatory shortcuts. Hainan's pilot-zone policy avoids a full NMPA approval, which management says can take a decade. Real-world data collected in Hainan would support both an Order 818 fast track and a formal NMPA filing [Money Today, Apr and Aug 2026].
-
US via partnership. Partnering or licensing for CartiLife's US Phase 3 was a stated BIO USA 2026 objective [Asia Economy, Jun 2026]. KHIDI-funded regulatory strategy supports FDA INDs for Cartiroid and Spherocure [Money Today, Sep 2026].
-
Cash-cow extension. Expanding KeraHeal-Allo into chronic wounds (a Korean market estimated at KRW 100–150bn) to fund pipeline development [Herald; Money Today, May 2026].
-
Helixmith synergies. Planned or announced areas [Dealsite, Mar 2025; Sep 2025]:
-
CDMO using Helixmith's Magok GMP plant.
-
CRO combining Helixmith's animal facility with Biosolution's GLP tissue models.
-
Health functional foods and cosmetic ingredients.
-
Complementary CAR-T programmes (αβ and γδ).
-
Use of Helixmith's US clinical network.
-
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Type | Status | Source |
|---|---|---|---|---|
| Jan 2025 | Helixmith restructuring under Jang: headcount cut from 160 to 45, pipeline from about 10 programmes to 3 | Transformation (associate) | Completed; Helixmith FY2025 net loss reduced to about KRW 0.4bn | Dealsite (Sep 2025); ETF Shopping |
| Feb–Jul 2025 | Cartiroid domestic IND (rejected), then pivot to Australia | Clinical | Australian Phase 1/2 approved January 2026 | Dealsite (Jul 2025); Money Today (Jan 2026) |
| Apr 2025 | CartiLife full approval; launch of full domestic sales push | Commercial | Ongoing; SNU Hospital added April 2026 | Dealsite (Jun 2025); Bloter (Apr 2026) |
| May 2025 | 200% bonus issue to improve liquidity in the shares | Capital markets | Completed | DART via ETF Shopping |
| Jun 2025 – Aug 2026 | Hainan programme: delegation visit, white list, local production, quality and equivalence testing, sales approval, price registration, Boao contract, first patient | New market launch | Commercial since August 2026 | Money Today; Hankyung; Dailypharm |
| Nov 2025 – Jul 2026 | Spherocure Korean Phase 1/2a | Clinical | IND approved July 2026; CRO J&P Medi reported as supporting | Hankyung (Jul 2026); TheVC |
| Mar 2026 | CB conversion; balance-sheet repair | Financial | Completed (about KRW 11.4bn converted) | TheBell (Mar 2026) |
| Apr 2026 | KeraSkin phototoxicity method adopted as OECD TG 498 | Tissue-model business | Completed | Hankyung (Apr 2026) |
| May 2026 | KeraHeal-Allo chronic-wound programme (4-year government grant) | New indication | Started | Herald (May 2026) |
| Jun 2026 | BIO USA partnering (CartiLife licensing; Cartiroid and Spherocure) | BD | No deal announced as of 15 Oct 2026 | Asia Economy (Jun 2026) |
| Jun–Sep 2026 | FDA Type C meeting on CartiLife Phase 3 design | Regulatory | Meeting held; Phase 3 IND targeted within 2026 | Money Today (Sep 2026); TheBell (Aug 2026) |
| Aug 2026 | CB maturity extension to August 2027 | Financial | Completed | Money Today (Aug 2026) |
| Sep 2026 | KHIDI global-expansion support for FDA INDs (Cartiroid, Spherocure) | Regulatory | Started | Money Today (Sep 2026) |
ESG / sustainability commitments
No formal emissions, climate or sustainability targets were identified. The tissue-model business directly supports the 3Rs (replacement of animal testing) and international bans on animal testing for cosmetics. This is the company's most material sustainability-linked activity.
Cost programmes
No cost programme with targets was disclosed at Biosolution. At Helixmith, SG&A fell from KRW 37.3bn (2023) to 20.8bn (2024) to about 10.8bn (2025, internal settlement) [TheBell, Feb 2026].
Medium-term targets and guidance
| Target | Status | Source |
|---|---|---|
| China: 1,000 CartiLife procedures in 2027 | Active | Money Today (Apr 2026) |
| 2025: domestic CartiLife break-even and an operating profit | Not achieved (FY2025 operating loss KRW 4.3bn) | Dealsite (Feb 2025) |
| CartiLife US Phase 3 IND submission within 2026 | Pending | TheBell (Aug 2026) |
| Formal revenue / margin guidance | — | — |
Products & Services
Cell therapeutics (marketed)
CartiLife® (카티라이프) — autologous chondrocyte therapy
Description: The patient's own costal (rib) cartilage cells are isolated and expanded ex vivo. They are then organised, without any artificial scaffold, into bead-shaped cartilage micro-tissue with self-produced extracellular matrix. The beads are implanted into knee cartilage defects [Dailypharm, Aug 2026; BioSpectator, 2018].
Differentiation claimed: No animal collagen scaffold (unlike Vericel's MACI). Costal chondroprogenitors are claimed to have good regenerative capacity regardless of patient age. Aims at hyaline (not fibro-) cartilage [Hankyung, Jan 2025; Bloter, Apr 2026].
Regulatory status: - Korea: conditional approval 24 Apr 2019; re-approved as an advanced biopharmaceutical in July 2021; full approval April 2025.
-
US: FDA RMAT designation; Phase 2 completed; Type C meeting on Phase 3 held by September 2026.
-
China: Hainan Boao Lecheng pilot-zone sales approval April 2026.
Clinical evidence: - Korean Phase 2: 30 patients (20 CartiLife vs 10 microfracture), with a 5-year follow-up published in AJSM.
-
Korean Phase 3: 104 patients (52 vs 52 microfracture). Statistically significant superiority on MOCART MRI score at 48 weeks and on secondary IKDC and KOOS endpoints.
-
US Phase 2: 20 patients, single arm, 4 sites (incl. Ohio, California, Texas). Endpoints MOCART and KOOS at 48 weeks; company reports positive trends. Sources: Biosolution IR book (Jan 2024); Hankyung (Mar 2025); TheBell (Aug 2026).
Target customer: Orthopaedic surgeons treating ICRS grade 3–4 cartilage defects, traumatic or OA-related, across adult age groups.
Pricing: - Korea: not publicly disclosed. A 2023 sell-side model assumed about KRW 8m per case [Research Arum, Mar 2023].
- China (Hainan): CNY 150,000 per treatment, rising to CNY 195,000 for larger defects. Total procedure cost about CNY 200,000 including hospital charges [Hankyung, May 2026; MediPharm Health, Apr 2026]. Biosolution's share of this price is not publicly disclosed.
Flagship status: The core product and the valuation anchor.
KeraHeal® (케라힐) — autologous keratinocyte spray
Description: Suspension of the patient's own skin-derived keratinocyte stem cells, sprayed directly onto extensive severe burns. Designed for large-area coverage without additional donor-site damage [company press release, Aug 2021; BioSpectator, 2018].
Status: Marketed. Re-approved as an advanced biopharmaceutical on 26 Aug 2021. Reimbursed under health insurance and industrial-accident insurance.
Customer: Burn-specialist hospitals.
Pricing: Not publicly disclosed.
KeraHeal-Allo® (케라힐-알로) — allogeneic keratinocyte hydrogel
Description: Allogeneic keratinocytes suspended in a thermosensitive hydrogel, supplied in a pre-filled syringe. Releases growth factors and cytokines (e.g., TGF-α, PDGF, bFGF, EGF, VEGF, IL-1α, FGF-2) that promote re-epithelialisation and angiogenesis. The gel format suits joints and irregular wounds [Medigate News, May 2016; Herald, May 2026].
Status: MFDS approval 16 Oct 2015. NHI and industrial-accident insurance listing November 2016. Advanced-biopharmaceutical re-approval August 2021. Marketed for roughly ten years.
Pivotal data: In 32 patients with deep second-degree burns of at least 200 cm², mean re-epithelialisation was 10.8 days on the treated site versus 13.6 days on control, a statistically significant 2.8-day difference [Medigate News, May 2016].
Development: Indication expansion to refractory chronic wounds (e.g., diabetic foot ulcers). Funded for four years by the multi-ministry Regenerative Medicine Technology Development programme (selected May 2026). Includes building an FDA-compliant master cell bank [Herald, May 2026].
Commercial partner: Mundipharma Korea held exclusive Korean distribution from 2016.
Cell therapeutics (clinical pipeline)
| Asset | Modality | Indication | Stage / status | Key design | Source |
|---|---|---|---|---|---|
| CartiLife (US) | Autologous costal chondrocyte beads | Knee cartilage defects | Phase 2 complete; FDA Type C meeting held for Phase 3; RMAT | Company targeted a Phase 3 IND submission within 2026 | TheBell (Aug 2026); Money Today (Sep 2026) |
| CartiLoiD® (카티로이드) | Allogeneic pellet-type 3D chondrocytes; off-the-shelf, mass-producible | Knee cartilage defects (ICRS 3–4, 2–10 cm²) | Australian Phase 1/2 approved 15 Jan 2026 (Bellberry HREC). Korean IND rejected June 2025. | 45 patients, multicentre, randomised vs microfracture | Money Today (Jan 2026); Dealsite (Jul 2025) |
| speroQure® (스페로큐어) | Allogeneic paediatric costal chondrocytes as 3D spheroids, intra-articular injection | Knee OA (Kellgren-Lawrence grade 2–3); DMOAD intent | Korean Phase 1/2a IND approved 13 Jul 2026 (filed Nov 2025) | Phase 1: up to 18 patients, dose escalation (DLT/MTD). Phase 2a: 41 or 68 patients, multicentre, randomised, placebo-controlled, double-blind. Endpoints: VAS and WOMAC at 24 weeks, MRI, biomarkers. | Hankyung; FN News; MediPharm Health (Jul 2026) |
| Gamma-delta CAR-T | Allogeneic γδ T-cell CAR | Oncology | Preclinical; complementary to Helixmith's αβ CAR-T | — | Dealsite (Sep 2025) |
| KeraHeal-Allo (chronic wounds) | Allogeneic keratinocytes | Refractory chronic wounds / ulcers | Government-funded development (4 years from 2026) | — | Herald (May 2026) |
Human tissue models and testing services
| Product / service | Description | Regulatory standing | Source |
|---|---|---|---|
| KeraSkin™ | Reconstructed human epidermis from human keratinocytes. Multilayer structure with functional stratum corneum. Used for chemical, cosmetic, device and drug safety and efficacy testing. | OECD TG 439 (skin irritation, adopted 2021); OECD TG 498 (phototoxicity, adopted April 2026, the second model worldwide after a US model); ISO-listed | Hankyung (Apr 2026); Newsis (May 2021) |
| MCTT HCE™ | Reconstructed human epithelial ("mucosal") model, used for eye-irritation testing | OECD TG 492 listing | Hankyung (Apr 2026) |
| Cartilage, intestinal and other models | Research models for efficacy and toxicity | — | Hankyung (Apr 2026) |
| GLP non-clinical testing | Alternative-to-animal testing services; dedicated KeraSkin / CRO site (keraskin.co.kr) | GLP certification from MFDS and the Ministry of Environment | Hankyung (Apr 2026); company website |
| Skin organoid standardisation | Participation in ISO/TC 276 WG 7 | — | Hankyung (Apr 2026) |
Biosolution says it is the only Korean company with alternative-test models (corneal and skin) listed in both OECD TGs and ISO [Hankyung, Apr 2026]. Pricing is not publicly disclosed.
Cosmetic ingredients and finished cosmetics
| Product | Description | Source |
|---|---|---|
| STEMSOO / STem水 | Human stem-cell conditioned-media cosmetic ingredient; also a B2C bio-cosmeceutical brand mall (stemsoo.com) | Company website; press release (Jul 2021) |
| BSP-11 | Ingredient containing skin-regenerating peptide "SP" | Press release (Jul 2021) |
| Cellopherin exosome | Exosome ingredient using proprietary isolation and concentration technology. Korean patent on enhanced exosome release granted May 2021. | Press release (Jul 2021); company site (May 2021) |
| Plant stem-cell and probiotic-derived exosomes | Natural-origin exosome ingredients | Press release (Jul 2021) |
| Natural cosmetic ingredients; human-derived ingredients | Functional and natural raw materials | Company website |
| Cosmetic ingredient development and consulting | Contract development services | Company website |
Medical devices / merchandise
| Product | Description | Status | Source |
|---|---|---|---|
| StemMobile-Gel | Wound-healing gel product. Company stated plans for UN procurement registration and overseas supply talks. | Export approval February 2021 | Company press release (Feb 2021) |
Financial Narrative
Income statement
Sources: DART business reports compiled by ETF Shopping; Butler; Hankyung (Feb 2026).
Notes:
FY2025 net income: ETF Shopping and Butler show KRW 0.3bn. The company's February 2026 announcement reported KRW 0.7bn. The difference most likely reflects attribution (controlling interest vs total) or preliminary vs audited figures. It is unresolved.
FY2023 net income: Butler shows KRW -1.2bn versus KRW -1.4bn at ETF Shopping.
FY2023 operating income: Butler shows KRW -5.0bn versus KRW -5.1bn.
EPS before FY2025: Reported on pre-bonus-issue share counts. The adjusted row divides by 3 to reflect the May 2025 2-for-1 bonus issue (analyst adjustment).
Pre-FY2023 basis: Separate statements.
Margins (%)
Source: ETF Shopping (DART-based). Bloter cites the FY2022 operating margin as -51.8% versus -52.4% here.
Revenue CAGR (derived):
-
FY2021–FY2025 (4-year): about 6.5%.
-
FY2020–FY2025 (5-year, from KRW 7.7bn in FY2020): about 14.6%.
Cost structure, FY2025
Sources: Bloter (Apr 2026); DART via ETF Shopping.
Quarterly trajectory
Sources: Google Finance (Q2 2025–Q1 2026); ETF Shopping (Q2 2026); Dailypharm (Q1 2026).
Notes:
-
Q1 2025 revenue and operating income are derived as the FY2025 total minus the three reported quarters.
-
Q1 2026 net income is derived from reported EPS of KRW -83 (Investing.com) and should be treated as approximate.
H1 2026 revenue: is about KRW 8.46bn versus about KRW 6.27bn in H1 2025, roughly +35% YoY (derived).
Balance sheet
Sources: Hankyung (Feb 2026); Bloter (Apr 2026); TheBell (Mar 2026).
Notes:
- FY2025 liabilities and equity are derived from total assets (KRW 68.9bn) and the reported 112% debt ratio. The result is consistent with the market-implied book value (KRW 143.8bn market cap ÷ 4.49× P/B ≈ KRW 32bn).
Additional data points: - Goodwill and intangibles. Not publicly disclosed in sources reviewed.
Investment in associate (Helixmith): Carrying value not publicly disclosed in sources reviewed. The original cost was KRW 36.5bn, plus further purchases including a reported KRW 3.4bn acquisition. An impairment was recognised (implied by a reversal of about KRW 4.8bn in FY2025).
Pro-forma debt ratio: The March 2026 conversion of about KRW 11.4bn of CB lowers the debt ratio to about 62% on a FY2025 pro-forma basis [TheBell, Mar 2026].
Cash flow
Source: ETF Shopping (FY2025 FCF).
-
Operating cash flow and capex by year are not publicly disclosed in sources reviewed.
-
The KRW 12.6bn CB repurchase in August 2024 was a debt buyback, not a share buyback.
-
The KRW 36.5bn Helixmith subscription (December 2023) was the dominant investing outflow of the period. It explains much of the fall in cash plus short-term instruments from about KRW 79bn (FY2021) to about KRW 12bn (FY2025).
Commentary: trends, inflections and drivers
Revenue. Revenue has grown unevenly: KRW 7.7bn (FY2020) → 11.8bn → 10.1bn → 12.5bn → 12.9bn → 15.2bn (FY2025). The FY2022 dip and FY2024 stall reflect CartiLife's slow uptake under conditional approval. A 2023 sell-side model projected CartiLife alone at KRW 12.8bn by FY2025 [Research Arum, Mar 2023]; total cell-therapy revenue (CartiLife plus burns) reached only KRW 9.9bn. FY2025's 17.9% growth came largely from cosmetics (+87%). H1 2026's roughly 35% growth, with a higher cell-therapy share, is the first sign of a post-approval CartiLife inflection. China royalties start only from August 2026 and are not yet visible.
Margins. Gross margin has been stable at 63–65% since FY2023, which is healthy for a cell-therapy manufacturer. The operating loss stems from an opex base (about KRW 13.9bn) that is roughly 1.5× gross profit; R&D alone is 49% of revenue. The operating loss narrowed from KRW 5.1bn to 4.3bn in FY2025. Q4 2025 (-0.48bn) and Q2 2026 (-0.5bn) show that the quarterly loss approaches break-even when quarterly revenue exceeds about KRW 4.5bn. This is the key operating-leverage observation.
Net income. Net income has been driven by non-operating items linked to Helixmith. The FY2024 net loss of KRW 11.9bn far exceeded the operating loss, consistent with equity-method losses and impairment of the Helixmith investment. The FY2025 swing to a small profit came mainly from a reversal of about KRW 4.8bn of that impairment as Helixmith's results and value recovered [Hankyung, Feb 2026]. Management described the turnaround as structural; the arithmetic shows it was largely accounting-driven.
Liquidity. Liquidity is the binding constraint. Cash plus short-term instruments fell from about KRW 79bn (FY2021) to about KRW 12bn (FY2025). The main uses were the Helixmith acquisition, cumulative operating losses, and the KRW 12.6bn CB repurchase. The current ratio fell from 178% to 57%. The March 2026 CB conversion repaired leverage but not cash. The August 2026 maturity extension moved the KRW 18bn external redemption risk to August 2027. With operating cash burn of roughly KRW 2–4bn a year (FY2025 FCF -1.5bn) plus Phase 3 ambitions, external funding or licensing income will likely be needed within 12–18 months unless China revenue scales quickly. That is the analyst's assessment.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Ownership | Latest total assets (KRW Bn) | Latest net income (KRW Bn) | Source |
|---|---|---|---|---|---|
Bio Solution Co., Ltd. | Parent (listed) | — | 68.9 (consolidated, FY2025) | 0.3–0.7 (see 6.1 note) | Hankyung (Feb 2026); ETF Shopping |
Bio Solution Australia Pty Ltd | Subsidiary | 100% | 1.75 | 0.053 | DART FY2025 via ETF Shopping |
Hainan Bio Solution Co., Ltd | Subsidiary | 100% | 0.21 | -0.058 | DART FY2025 via ETF Shopping |
Helixmith Co., Ltd. (KOSDAQ: 084990) | Associate (equity method) | 18.23–18.25% | 143.2 | -0.44 | DART FY2025 via ETF Shopping; Hankyung (Feb 2026) |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cell therapeutics revenue (KRW Bn) | 5.9 | 7.5 | 10.1 | 9.5 | 9.9 |
Cosmetic materials revenue (KRW Bn) | — | — | 1.0 | 1.5 | 2.8 |
Human tissue models revenue (KRW Bn) | — | — | 1.1 | 1.3 | 1.5 |
Merchandise and other services revenue (KRW Bn, derived residual) | — | — | 0.3 | 0.6 | 1.0 |
Total revenue (KRW Bn) | 11.8 | 10.1 | 12.5 | 12.9 | 15.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cell therapeutics share (%) | 80.6 | 73.6 | 65.3 |
Cosmetic materials share (%) | 8.2 | 12.0 | 18.7 |
Human tissue models share (%) | 8.8 | 10.0 | 10.1 |
Merchandise and other share (%) | 2.4 | 4.4 | 5.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%)
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cell therapeutics growth (%) | 34.7 | -5.9 | 4.2 |
Cosmetic materials growth (%) | — | 50.0 | 86.7 |
Human tissue models growth (%) | — | 18.2 | 15.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 11.8 | 10.1 | 12.5 | 12.9 | 15.2 |
Revenue growth YoY (%) | 52.4 | -14.4 | 23.4 | 3.4 | 17.9 |
Cost of sales (KRW Bn) | 4.2 | 4.2 | 4.4 | 4.7 | 5.6 |
Gross profit (KRW Bn) | 7.6 | 5.9 | 8.1 | 8.2 | 9.6 |
Operating income (KRW Bn) | -1.6 | -5.3 | -5.1 | -5.1 | -4.3 |
EBITDA (KRW Bn) | 0.0 | -3.3 | -2.6 | -3.2 | -2.5 |
Net income (KRW Bn) | -1.7 | -8.1 | -1.4 | -11.9 | 0.3 |
EPS as reported (KRW) | -211 | -1,009 | -169 | -496 | 11 |
EPS adjusted for 2025 bonus issue (KRW, derived) | -70 | -336 | -56 | -165 | 11 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 64.5 | 58.7 | 64.7 | 63.3 | 63.1 |
Operating margin (%) | -13.3 | -52.4 | -41.3 | -39.3 | -28.6 |
EBITDA margin (%) | 0.4 | -32.5 | -20.8 | -24.8 | -16.5 |
Net margin (%) | -14.3 | -80.1 | -10.9 | -92.6 | 1.8 |
Key Financials and Margin Analysis (%)
| Metric | FY2025 |
|---|---|
SG&A incl. R&D (KRW Bn) | 13.9 |
SG&A incl. R&D as share of revenue (%) | 91.6 |
R&D expense (KRW Bn) | 7.5 |
R&D as share of revenue (%) | 49.4 |
Total payroll (KRW Bn) | 5.67 |
Payroll as share of revenue (%) | 37.3 |
Average salary per employee (KRW Mn) | 56.73 |
Income Statement
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 3.14 | 3.13 | 4.51 | 4.42 | 3.76 | 4.70 |
Cost of revenue (KRW Bn) | — | 1.29 | 1.70 | 1.53 | 1.31 | — |
R&D expense (KRW Bn) | — | 1.34 | 2.06 | 1.22 | 1.51 | — |
SG&A ex-R&D (KRW Bn) | — | 1.53 | 1.73 | 1.87 | 1.98 | — |
Operating income (KRW Bn) | -1.34 | -1.38 | -1.10 | -0.48 | -1.30 | -0.50 |
Net income (KRW Bn) | — | — | — | — | -2.1 | -0.7 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | — | — | — | 67.4 | 68.9 |
Cash and cash equivalents (KRW Bn) | 29.0 | — | — | — | 11.9 |
Short-term financial instruments (KRW Bn) | 50.2 | — | — | — | 0.2 |
Bank borrowings, short and long-term (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Total liabilities (KRW Bn, derived) | — | — | — | — | 36.4 |
Total equity (KRW Bn, derived) | — | — | — | — | 32.5 |
Current ratio (%) | 178.2 | — | — | — | 56.7 |
Liabilities to equity (%) | — | — | — | — | 112 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansData Point by Date
| Date | Data point | Source |
|---|---|---|
End Q3 2024 | Cash and equivalents about KRW 8.5bn | Dealsite (Feb 2025) |
End Q1 2026 | Cash and equivalents KRW 11.2bn | Dailypharm (Aug 2026) |
Financial Analysis
| Item | Detail | Source |
|---|---|---|
Instrument | 1st-series private CB, issued August 2021, KRW 42.0bn face. Zero coupon. | Money Today (Aug 2026) |
Repurchased by company | KRW 12.6bn via call option (August 2024), held as treasury CB | Money Today (Aug 2026) |
Converted | KRW 10.0bn (Wonik) plus KRW 1.4bn (Eum) in March 2026 at KRW 6,986 | Money Today (Aug 2026); TheBell (Mar 2026) |
Outstanding with external holders | KRW 18.0bn (Wonik) | Dailypharm (Aug 2026) |
Maturity (extended) | 13 August 2027 (from 13 August 2026). Maturity yield raised from 1% to 4% for the extension year. | Money Today (Aug 2026) |
Conversion price | KRW 6,986 (vs KRW 5,920 share price on 15 Oct 2026) | Money Today; ETF Shopping |
Net debt (derived, face value) | About KRW 6.8bn: external CB KRW 18.0bn minus end-Q1 2026 cash KRW 11.2bn. On a FY2025 year-end basis (external CB KRW 29.4bn face minus KRW 12.1bn cash and STFI) about KRW 17.3bn. | Derived |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Free cash flow (KRW Bn) | — | — | — | — | -1.5 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Income Statement
| Ratio | FY2025 | Source / note |
|---|---|---|
ROE (%) | 0.9 | ETF Shopping |
ROA (%) | 0.4 | ETF Shopping |
ROIC (%) | Negative (operating loss) | Derived |
Current ratio (%) | 56.7 | Bloter |
Liabilities / equity (%) | 112 (about 62 pro forma after March 2026 conversion) | TheBell |
Net debt / EBITDA | Not meaningful (negative EBITDA) | Derived |
Interest coverage | Not meaningful (operating loss; zero-coupon CB) | Derived |
Asset turnover (x) | About 0.22 (15.2 / 68.9) | Derived |
Revenue per employee (KRW Bn) | 0.15 | DART via ETF Shopping |
Segment × Geography Details
| Segment × geography | Korea | China | Australia | Other export |
|---|---|---|---|---|
Cell therapeutics | Essentially all revenue to FY2025 (hospital sales, reimbursed burn products) | Commercial from August 2026 (first patient); technology-fee model | Clinical only (Cartiroid trial) | US: clinical only |
Cosmetic materials | Majority (B2B ingredient sales; stemsoo.com) | — | — | — |
Tissue models / GLP testing | Majority | — | — | — |
Medical devices | — | — | — | StemMobile-Gel export approval (2021); sales not disclosed |
“—” = not publicly disclosed.
Geographic Revenue
| Metric | Bio Solution Australia | Hainan Bio Solution |
|---|---|---|
Total assets (KRW Bn) | 1.75 | 0.21 |
Net income (KRW Bn) | 0.053 | -0.058 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Close, 15 Oct 2026 | KRW 5,920 | ETF Shopping |
Market capitalisation | KRW 143.8bn | ETF Shopping |
52-week range | KRW 5,510–12,950 (ETF Shopping) vs KRW 5,240–13,450 (Google / Investing, earlier windows) | ETF Shopping; Investing.com |
1-month return (%) | -8.2 | ETF Shopping |
6-month return (%) | -50.5 | ETF Shopping |
1-year return (%) | -27.0 | ETF Shopping |
3-year return (%) | Indicative only: about KRW 20,300 pre-bonus on 3 Jan 2024 (≈KRW 6,770 adjusted) implies roughly -13% since then. | SmartToday (Jan 2024); derived |
5-year return (%) | Indicative only: market cap about KRW 250bn in April 2021 vs KRW 143.8bn now (share count broadly similar after adjusting for the bonus issue). | Dealsite (Apr 2021); derived |
Share Count (m)
| Metric | FY2016 | FY2025 | Post-Mar 2026 |
|---|---|---|---|
Shares outstanding (m) | 6.13 | 24.29 | 25.92 |
Valuation Multiples
| Multiple | Biosolution | Basis / note | Source |
|---|---|---|---|
P/E (trailing) | 538× (on FY2025 EPS KRW 11) or about 210–218× (TTM, other providers) | Not meaningful; earnings are associate-driven | ETF Shopping; Google; StockHub |
P/E (forward) | 30.4× | Provider estimate; basis undisclosed; zero sell-side reports in sample | StockHub |
P/B | 4.49× | On FY2025 book equity | ETF Shopping |
EV/Sales | About 9.9× FY2025 sales; about 8.7× TTM sales (KRW 17.4bn, Q3 2025–Q2 2026) | Derived: EV ≈ market cap 143.8bn + external CB 18.0bn − cash 11.2bn ≈ KRW 150.6bn | Derived |
EV/EBITDA | Not meaningful (negative EBITDA) | — | Derived |
Research Provider by Date
| Date | Research provider | Type | Note |
|---|---|---|---|
Jun 2026 | ValueFinder | Independent research | Highlighted China and BD; no target price retrieved |
Apr 2026 | NH Investment & Securities (Shim Eui-seop) | Analyst comment | Re-rating thesis built on Spherocure and Cartiroid |
Jul 2024 | KIRS | Sponsored research | — |
Mar 2023 | Research Arum | Independent research | Target price KRW 25,000 pre-bonus (≈KRW 8,333 adjusted) |
Jun 2020 | Yuanta | Broker report | — |
Mar 2020 | IBK | Broker report | — |
Capital Markets
| Item | Detail | Source |
|---|---|---|
Dividend history | No dividends paid (dividend yield 0.00%) | ETF Shopping |
Dividend policy | None disclosed | — |
Buyback authorisations | None disclosed. Treasury shares about 0.46–0.49%. The CB call-option repurchase (KRW 12.6bn, August 2024) was a debt buyback. | Butler; ETF Shopping; Money Today |
Credit ratings (Moody's / S&P / Fitch) | None (unrated) | — |
Capital Instruments
| Instrument | Face (KRW Bn) | Maturity | Coupon / YTM | Conversion price (KRW) |
|---|---|---|---|---|
1st-series CB, external (Wonik) | 18.0 | 13 Aug 2027 | 0% / 4% | 6,986 |
1st-series CB, self-held | 12.6 | 13 Aug 2027 | 0% / 4% | 6,986 |
Bank borrowings | 0 | — | — | — |
Analyst Conclusions
Management guidance and consensus
No formal financial guidance: has been published.
Qualitative guidance: [TheBell, Jan and Aug 2026; Money Today, Apr 2026]:
-
Revenue expansion is the 2026 priority.
-
1,000 Chinese procedures targeted for 2027.
-
CartiLife US Phase 3 IND targeted within 2026.
-
Spherocure and Cartiroid FDA IND preparation.
Consensus: none available.
Run-rate observation: H1 2026 revenue of about KRW 8.5bn (+35% YoY) and a Q2 2026 operating loss of only KRW 0.5bn imply that a full-year FY2026 revenue of about KRW 17–19bn is plausible. This is the analyst's extrapolation, not guidance; it assumes H2 is at least equal to H1 before China contributions.
Bull case
-
China becomes a high-margin royalty stream.
-
At CNY 150–195k per treatment, 1,000 procedures in 2027 would put gross treatment value at CNY 150–195m, roughly KRW 30bn+ at the price levels cited in Korean press.
-
Even a modest technology-fee share could double group revenue with little incremental cost [Hankyung, May 2026; Money Today, Apr and Aug 2026]. Biosolution's share is undisclosed.
-
-
Operating leverage is close. Gross margin is about 63%. Quarterly operating losses near break-even occur when revenue exceeds KRW 4.4–4.7bn (Q4 2025, Q2 2026). The domestic CartiLife ramp after full approval and SNU Hospital adoption could carry the company to operating profit [Google Finance; ETF Shopping].
-
Pipeline and associate optionality are cheap.
-
EV of about KRW 150bn buys a marketed, RMAT-designated product plus two clinical-stage allogeneic assets.
-
It also buys an 18% stake in Helixmith, which has about KRW 77bn of cash and financial assets (Q2 2025), a building of about KRW 120bn, and new China royalty rights [Dealsite, Sep 2025; Herald, May 2026].
-
Bear case
-
Funding squeeze.
-
Cash is about KRW 11bn against an annual burn of about KRW 2–5bn.
-
KRW 18bn of external CB is due in August 2027, and the share price is below the KRW 6,986 conversion price.
-
Absent licensing income, a dilutive raise or reissue of the KRW 12.6bn treasury CB is likely [Dailypharm, Aug 2026].
-
-
Core franchise under-delivers.
-
Cell-therapy revenue was flat at about KRW 10bn for three years.
-
The 2025 profitability goal was missed.
-
The 2023 sell-side model's KRW 12.8bn CartiLife-alone forecast for 2025 exceeded actual total cell-therapy revenue (KRW 9.9bn) [Research Arum, Mar 2023; Bloter, Apr 2026].
-
-
Earnings quality and execution risk.
-
Reported profits depend on Helixmith marks.
-
The US Phase 3 needs a partner that has not appeared after two BIO USA cycles.
-
Cartiroid was rejected in Korea.
-
OA trial risk is high (TG-C read-across).
-
China revenue depends on provincial policy and one partner hospital [Hankyung, Feb 2026; Dealsite, Jul 2025; TheBell, Aug 2026].
-
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Mid-Nov 2026 | Q3 2026 report: first quarter with Hainan procedures; cell-therapy revenue trend; cash balance |
| Q4 2026 | Submission of CartiLife US Phase 3 IND (company target within 2026); FDA response |
| Q4 2026 – 2027 | Hainan procedure count versus the 1,000-in-2027 target; disclosure of royalty or fee economics; Guangzhou / Order 818 mainland approval |
| Rolling | Any CartiLife, Cartiroid or Spherocure licensing deal |
| 2026–2027 | Spherocure Phase 1 first-patient-in and dose-escalation completion; Cartiroid Australian enrolment |
| Late 2026 | China NRDL / price outcome for NL003 (Helixmith royalties; Helixmith valuation feeds Biosolution P&L) |
| By Aug 2027 | CB resolution: conversion (requires price above KRW 6,986), redemption or refinancing; disposal of the KRW 12.6bn treasury CB |
| March 2027 | FY2026 business report; whether operating loss narrows below KRW 3bn |
Analyst verdict
Biosolution is a credible regenerative-medicine company with a weak balance sheet. On science and regulation it has outperformed its size:
-
CartiLife is one of very few cell therapies globally with an active-comparator Phase 3 showing structural superiority over microfracture.
-
It holds 5-year durability data, FDA RMAT status, a completed US Phase 2 and full Korean approval.
-
It has reached commercial status in China's Hainan pilot zone at a premium price.
-
The tissue-model franchise has international standards standing that peers cannot easily replicate.
On commercial and financial delivery, the record is weaker:
-
Revenue has compounded only about 6.5% a year since FY2021.
-
Cell-therapy sales have been flat at about KRW 10bn for three years.
-
Operating losses have persisted for five years.
-
The one profitable year (FY2025) owed its result to an accounting reversal on Helixmith.
-
Liquidity has been reduced to about KRW 11bn, in large part by the Helixmith purchase. That deal looked opportunistic when it closed, days before Engensis failed in DPN. It has since been partly vindicated by Helixmith's turnaround and Engensis's May 2026 approval in China.
The equity story for the next 12–18 months rests on three questions:
-
Can China turn into visible, recurring fee income fast enough?
-
Can a US partner be signed for CartiLife's Phase 3?
-
Can the August 2027 CB be resolved without heavy dilution?
At about 9–10× EV/sales, the market is paying for some of that optionality but not all of it. The 50% share-price fall over six months reflects scepticism that the China ramp and partnering will arrive before funding needs do.
Assessment. This is a high-risk, catalyst-driven situation rather than a fundamentals-led investment. Conviction should be gated on the Q3–Q4 2026 China procedure numbers and fee disclosure, and on any licensing deal. A credible partner-funded US Phase 3 combined with steady Hainan volumes would justify a material re-rating. A further quarter of flat cell-therapy sales and no partner would point to dilution ahead of the 2027 maturity.
-
ISIN; auditor; full board roster and committee structure; individual executive compensation; executive ages.
-
Geographic revenue split; segment operating income; CartiLife-only revenue; Korean CartiLife price and reimbursement status.
-
FY2021–FY2024 balance-sheet detail, operating cash flow and capex; R&D spend before FY2025.
-
Goodwill and intangibles; Helixmith carrying value.
-
Biosolution's percentage share of Hainan treatment price; identity of the Chinese sales partner.
-
Patent grants in 2025–2026; ESG ratings; emissions data.
-
Final 2018 IPO price; date of the name change from MCTT; status of the Mundipharma distribution agreement.
-
Peer valuation multiples.
APPENDIX B — PRINCIPAL SOURCES
Filings and company materials:
-
DART business reports FY2021–FY2025 (rcpNo 20220322000366, 20230321000662, 20240320000998, 20250328002208, 20260319001181), via ETF Shopping (etfshopping.com/stock/086820 and /company).
-
Biosolution corporate website (biosolutions.co.kr); Biosolution IR book (January 2024).
-
Company press releases (2021).
Korean financial and trade press:
-
Hankyung (2025–2026); Money Today / TheBell (2025–2026); Dailypharm (2023–2026).
-
Dealsite (2021–2025); Medical Times (2019, 2026); Medigate News (2016, 2019, 2026).
-
MediPharm Health (2025–2026); Bloter via Daum (April 2026); Herald (May 2026).
-
FN News (July 2026); Asia Economy (June 2026); BioSpectator (2018); Bizwatch, SmartToday, Newdaily (Dec 2023–Jan 2024).
-
DigitalToday (Sep 2025); Pressian.
Research:
- KIRS (Jul 2024); Research Arum (Mar 2023); Yuanta (Jun 2020); IBK (Mar 2020).
Market data:
- Simply Wall St; Google Finance; Investing.com; Morningstar; StockHub; Butler; Bullstory; TheVC.
Peers:
- Vericel Corporation FY2025 results release (Feb 2026); Medipost FY2025 results (Medigate News, Mar 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / history | Education / background | Source |
|---|---|---|---|---|
Lee Jung-sun (이정선) | CEO (대표이사) | Named as CEO in April 2019 and 2019–2020 announcements. Served as president under CEO Jang (2020–2024). Sole/lead CEO after Jang stepped down in H2 2024. | Konkuk University (veterinary medicine); post-doc at Korea Institute of Radiological & Medical Sciences; delegate of the Korean Society for Stem Cell Research. Previously R&D head (CTO), COO & CFO, and lab head for tissue-model development. | Biosolution IR book (Jan 2024); Medical Times (Apr 2019) |
Jang Song-sun (장송선) | Board chair (이사회의장); largest shareholder. Also Helixmith CEO since January 2025. | Led the company from 2005. Stepped down as CEO before the 2016 listing attempt; returned 2020; resigned as CEO H2 2024. | Chung-Ang University College of Medicine | Dealsite (Mar 2025); IR book (Jan 2024); Money Today (Apr 2026) |
Yoon Jung-hyun (윤정현) | Former CEO (at 2018 IPO) | CEO during 2018 listing | — | BioSpectator (2018) |
Jung Ji-wook (정지욱) | Former VP at Biosolution; Helixmith CEO from early 2024 (succeeded by Jang in January 2025) | — | — | Dealsite; SmartToday (Jan 2024) |
Lee Su-hyun (이수현) | Head, Non-clinical Center | — | — | Hankyung (Apr 2026) |
“—” = not publicly disclosed.
Workforce Metrics
| Item | Amount | Source |
|---|---|---|
Average pay per director / auditor (6 persons) | KRW 140m | DART FY2025 via ETF Shopping |
Multiple of average employee pay | 2.4× | DART FY2025 via ETF Shopping |
Individuals paid ≥KRW 500m | None disclosed (Korean rules require individual disclosure only at or above KRW 500m) | DART via ETF Shopping |
Major Shareholders
| Holder | Relationship | Stake (%) | Source |
|---|---|---|---|
Jang Song-sun | Largest shareholder | 17.6 | DART via ETF Shopping |
Lee Jung-sun | Officer | 0.86 | DART via ETF Shopping |
Bio Solution Co., Ltd. (treasury) | Treasury shares | 0.49 | DART via ETF Shopping |
Chang Nicole Hyesoo | Relative | 0.34 | DART via ETF Shopping |
Largest shareholder plus related parties | Total | 19.3 | DART via ETF Shopping |
National Pension Service | Institutional (end-2023 disclosure) | 0.15 | ETF Shopping |
Employee Stock Ownership Association | — | 0.04 | Investing.com |
Minority shareholders (9,244 holders) | Retail / other | 76.58 | DART via ETF Shopping |
Competitive Landscape
Key Competitors
| Competitor | Product | Positioning vs Biosolution | Latest financials (verified) | Source |
|---|---|---|---|---|
Vericel Corp. (Nasdaq: VCEL, US) | MACI (autologous chondrocytes on porcine collagen membrane); MACI Arthro | Global leader and the benchmark Biosolution compares itself to; US-only commercial today | FY2025 revenue USD 276.3M (+16%); MACI USD 239.5M (+21%); gross margin 74%; adj. EBITDA margin 26%; GAAP net income USD 16.5M. 2026 guidance: revenue USD 316–326M, MACI USD 280–286M. | Vericel FY2025 release (Feb 2026) |
Medipost (KOSDAQ: 078160, Korea) | Cartistem (allogeneic umbilical-cord-blood MSC for knee cartilage) | Most direct Korean rival in surgical cartilage regeneration. Larger scale. US Phase 3 IND (February 2026); Japan licence with Teikoku (December 2025). | FY2025 consolidated revenue KRW 73.6bn, operating loss KRW 67.9bn; separate revenue KRW 76.8bn, operating profit KRW 1.6bn | Medigate News (Mar 2026) |
Kolon TissueGene (KOSDAQ, Korea/US) | TG-C (Invossa; allogeneic chondrocytes plus TGF-β1 cells) | Injectable OA competitor to Spherocure | — | TheBell (Aug 2026) |
Sewon Cellontech (Korea) | RMS Chondron (autologous chondrocytes) | Legacy Korean ACI competitor to CartiLife | — | Company website keywords |
Nature Cell (Korea) | JointStem (autologous adipose MSC for knee OA) | Injectable OA competitor | — | Company website keywords |
Kangstem Biotech (Korea) | Stem-cell OA candidate | Injectable OA competitor | — | Company website keywords |
PharmaResearch (KOSDAQ: 214450, Korea) | Conjuran (polynucleotide intra-articular injection) | Symptomatic OA injectable competing for early-OA patients | — | Company website keywords |
CO.DON (Germany) | Spherox (autologous chondrocyte spheroids; EU-approved) | Closest conceptual analogue to CartiLife and Spherocure in Europe | — | — |
Japan Tissue Engineering (J-TEC, Japan) | JACC autologous cartilage | Japanese ACI incumbent | — | — |
Key Competitors — Tego Science
| Competitor | Product | Notes | Source |
|---|---|---|---|
Tego Science (Korea) | Kaloderm (allogeneic keratinocyte sheet), Holoderm | Direct competitor to KeraHeal-Allo; co-promotion with SK Chemicals (2021) | Medigate News (Aug 2021) |
Vericel | Epicel (cultured epidermal autografts), NexoBrid | Global burn-care analogue; FY2025 burn care revenue USD 36.8M | Vericel FY2025 release |
Peer Comparison FY2025
| Metric | Biosolution | Vericel | Medipost | Kolon TissueGene |
|---|---|---|---|---|
Revenue | KRW 15.2bn | USD 276.3M | KRW 73.6bn (consolidated) | — |
Revenue growth (%) | 17.9 | 16 | 4.2 | — |
Gross margin (%) | 63.1 | 74 | — | — |
Operating margin (%) | -28.6 | EBITDA margin 26) | about -92 (derived: -67.9 / 73.6) | — |
R&D intensity (%) | 49.4 | — | — | — |
Lead cartilage asset stage | Marketed (KR, Hainan); US Phase 3 planning | Marketed (US) | Marketed (KR); US Phase 3; Japan filing | US Phase 3 |
Recent Developments
*Layoffs / hiring. Headcount rose from 88 to 100 in FY2025. Helixmith cut from 160 to 45 staff [Dealsite, Sep 2025].
*Litigation.



